Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas

Genes Chromosomes and Cancer

Volumn 47, Issue 8, 2008, Pages 657-664

  Kersting, Christian ^a   Agelopoulos, Konstantin ^a   Schmidt, Hartmut ^a   Korsching, Eberhard ^a   August, Christian ^a   Gosheger, Georg ^a   Dirksen, Uta ^a   Juergens, Heribert ^a   Winkelmann, Wilfried ^a   Brandt, Burkhard ^b   Bielack, Stefan ^c,d   Buerger, Horst ^a,d   Gebert, Carsten ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c OLGAHOSPITAL   (Germany)

^d Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE;

5' UNTRANSLATED REGION; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE DELETION; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; INFANT; INTRON; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULAR BIOLOGY; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TRANSCRIPTION REGULATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ALLELES; DINUCLEOTIDE REPEATS; GENES, ERBB-1; HUMANS; INTRONS; OSTEOSARCOMA; POLYMORPHISM, GENETIC;

EID: 45349105094     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20571     Document Type: Article

References (29)

1. Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M. 2004. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64:9139-9143.
2. Atiye J, Wolf M, Kaur S, Monni O, Bohling T, Kivioja A, Tas E, Serra M, Tarkkanen M, Knuutila S. 2005. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 42:158-163.
3. Bielack SS, Jurgens H. 2004. Surgical expertise and outcome in osteosarcoma trials. J Clin Oncol 22:2511-2513.
4. Bielack SS, Kempf-Bielack B, Heise U, Schwenzer D, Winkler K. 1999. Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. J Clin Oncol 17:1164.
5. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. 2002. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790.
6. Brandt B, Hermann S, Straif K, Tidow N, Buerger H, Chang-Claude J. 2004. Modification of Breast Cancer Risk in Young Women by a Polymorphic Sequence in the egfr Gene. Cancer Res 64:7-12.
7. Brandt B, Meyer-Staeckling S, Schmidt H, Agelopoulos K, Buerger H. 2006. Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response. Clin Cancer Res 12:7252-7260.
8. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, Lelle R, Boecker W, Brandt B. 2000. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60:854-857.
9. Buerger H, Packeisen J, Boecker A, Tidow N, Kersting C, Bielawski K, Isola J, Yatabe Y, Nakachi K, Boecker W, Brandt B. 2004. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence-first results of an inter-ethnic breast cancer study. J Pathol 203:545-550.
10. Gebhardt F, Zanker KS, Brandt B. 1999. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274:13176-13180.
11. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC. 2002. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38:1218-1225.
12. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. 2004. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64:2047-2053.
13. Hulsebos TJ, Bijleveld EH, Oskam NT, Westerveld A, Leenstra S, Hogendoorn PC, Bras J. 1997. Malignant astrocytoma-derived region of common amplification in chromosomal band 17p12 is frequently amplified in high-grade osteosarcomas. Genes Chromosomes Cancer 18:279-285.
14. Kersting C, Tidow N, Schmidt H, Liedtke C, Neumann J, Boecker W, Diest PJ, Brandt B, Buerger H. 2004. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 84:582-587.
15. Kersting C, Kuijper A, Schmidt H, Packeisen J, Liedtke C, Tidow N, Gustmann C, Hinrichs B, Wulfing P, Tio J, Boecker W, Van Diest P, Brandt B, Buerger H. 2006a. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest 86:54-61.
16. Kersting C, Packeisen J, Leidinger B, Brandt B, von Wasielewski R, Winkelmann W, van Diest PJ, Gosheger G, Buerger H. 2006b. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol 59:585-590.
17. Kersting C, Gebert C, Agelopoulos K, Schmidt H, van Diest PJ, Juergens H, Winkelmann W, Kevric M, Gosheger G, Brandt B, Bielack S, Buerger H. 2007. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res 13:2998-3005.
18. Kreuter M, Bieker R, Bielack SS, Auras T, Buerger H, Gosheger G, Jurgens H, Berdel WE, Mesters RM. 2004. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res 10: 8531-8537.
19. Oda Y, Wehrmann B, Radig K, Walter H, Rose I, Neumann W, Roessner A. 1995. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: Its correlation with proliferating activities and p53 expression. Gen Diagn Pathol 141:97-103.
20. Ozaki T, Schaefer KL, Wai D, Buerger H, Flege S, Lindner N, Kevric M, Diallo R, Bankfalvi A, Brinkschmidt C, Juergens H, Winkelmann W, Dockhorn-Dworniczak B, Bielack SS, Poremba C. 2002. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer 102:355-365.
21. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. 1983. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol 106:21-24.
22. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. 2004. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85.
23. Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J, Bohling T, Karaharju E, Hyytinen E, Knuutila S. 1995. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 55:1334-1338.
24. van Dartel M, Cornelissen PW, Redeker S, Tarkkanen M, Knuutila S, Hogendoorn PC, Westerveld A, Gomes I, Bras J, Hulsebos TJ. 2002. Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. Cancer Genet Cytogenet 139:91-96.
25. Wolf M, El Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, Elomaa I, Kallioniemi A, Kallioniemi OP, Knuutila S. 2000. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet 123:128-132.
26. Zhang W, Stoehlmacher J, Park DJ, Groshen S, Tsao-Wei D, Zahedy S, Lu B, Gil J, Mallik N, Lenz HJ. 2002. A polymorphic dinucleotide repeat in intron 1 of EGFR (epidermal growth factor receptor) gene is associated with clinical response to platinum based chemotherapy in patients with advanced colorectal disease. Proc Am Soc Clin Oncol 21:134.
27. Zhang W, Park DJ, Lu B, Yang DY, Gordon M, Groshen S, Yun J, Press OA, Vallbohmer D, Rhodes K, Lenz HJ. 2005a. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 11:600-605.
28. Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, Tsao-Wei DD, Yun J, Gordon M, Press OA, Rhodes K, Groshen S, Lenz HJ. 2005b. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer 5:124-131.
29. Zhang W, Gordon M, Press OA, Rhodes K, Vallbohmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. 2006. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 16:475-483.